Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study

agirgol, muharrem; agirgol, senay

doi:10.4274/haseki.galenos.2021.6704

Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study

Şenay AĞIRGÖL, (Türkiye Sağlık Bilimleri Üniversitesi, İstanbul Haseki Eğitim ve Araştırma Hastanesi, Dermatoloji Kliniği, İstanbul, Türkiye)

Muharrem AĞIRGÖL (Türkiye Sağlık Bilimleri Üniversitesi, İstanbul Haseki Eğitim ve Araştırma Hastanesi, Eczacılık Kliniği, İstanbul, Türkiye)

Haseki Tıp Bülteni

7 0

Yıl: 2021 Cilt: 59 Sayı: 3 Sayfa Aralığı: 239 - 244 Metin Dili: İngilizce DOI: 10.4274/haseki.galenos.2021.6704 İndeks Tarihi: 17-11-2021

Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study

Öz:

Aim: As skin disorders may be observed with Hepatitis C, direct-acting antiviral drugs (DAA), dermatological side effects are alsoreported. The objective is to determine the dermatological side effects of DAA drugs.Methods: A study was conducted with chronic hepatitis C patients who used Ombistavir/Paritaprevir/Ritonavir + Dasabuvir (Group1), Sofosbuvir + Ledispavir (Group 2), and sofosbuvir (Group 3) and who supplied the drugs from our hospital. Skin examinations ofthe patients regarding dermatological side effects were conducted. Patients with dermatological side effects and treatment modalitieswere followed.Results: One hundred twelve patients were using Group 1; 69 were using Group 2, 19 were using Group 3. All pruritus patients werein Group 1. It was detected in 56 of 200 patients (28%). Pruritus was more prevalent in patients with diabetes mellitus, hypertension,and heart disease, and the drug could be tolerated in those with no additional systemic comorbidities. Thirty-one patients had renalfailure, and 17 of them underwent renal transplantation, and the pruritus rate was high (57%) in the chronic renal disease Group.Conclusion: Pruritus is the most common side effect observed with DAA drugs used in treating hepatitis C and elderly patients, andpatients with comorbidity and renal transplantation are at high risk.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
2. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801.
3. Arends JE, Kracht PA, Hoepelman AI; European Study Group for Viral Hepatitis (ESGVH). Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clin Microbiol Infect 2016;22:846-52.
4. Suntur BM, Kaya H, Eker HBŞ, Kara B, Bozok T, Unal N. A cross-sectional study of real life data of HCV from Turkey south region. J Infect Dev Ctries 2020;14:380-6.
5. Kirdar S, Aydin N, Tiryaki Y, Ertugrul B, Coskun A, Bilgen M. Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factors. APMIS 2018;126:109-13.
6. Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, Şeydaoğlu G, Özkarataş E, Abacıoğlu H. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol 2020;31:128-35.
7. Goetsch MR, Tamhane A, Varshney M, et al. Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/ Creatinine Ratios. Pathog Immun 2017;2:366-75.
8. Mikolas LA, Jacques K, Huq M, Krasner C, Mambourg SE. Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy. J Pharm Pract 2019;32:655-63.
9. Bourlière M, Pietri O. Hepatitis C virus therapy: No one will be left behind. Int J Antimicrob Agents 2019;53:755-60.
10. Piecha F, Gänßler JM, Ozga AK, et al. Treatment and retreatment results of HCV patients in the DAA era. PLoS One. 2020;15:0232773.
11. Chung CM, Nunley JR. Overview of hepatitis C and skin. Dermatol Nurs 2006;18:425-30.
12. Cacoub P, Bourlière M, Lübbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012;56:455- 63.
13. Cheung AC, Patel H, Meza-Cardona J, Cino M, Sockalingam S, Hirschfield GM. Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. Dig Dis Sci 2016;61:1692-9.
14. Gutteling JJ, de Man RA, Busschbach JJ, Darlington AS. Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 2007;65:227- 34.
15. Dervis E, Serez K. The prevalence of dermatologic manifestations related to chronic hepatitis C virus infection in a study from a single center in Turkey. Acta Dermatovenerol Alp Pannonica Adriat 2005;14:93-8.
16. Stauber RE, Fauler G, Rainer F, et al. Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus. Wien Klin Wochenschr 2017;129:848-51.
17. Tawfik YM, Hassany SM, Badran AY, El-Gazzar AF, Alemam MF, Sayed DS. Hepatitis C virus associated skin manifestations in upper Egypt: Before and after direct acting antiviral treatment. Dermatol Ther 2020;33:14365.
18. Rebora A. Skin diseases associated with hepatitis C virus: facts and controversies. Clin Dermatol 2010;28:489-96.
19. Ferreira VL, Borba HHL, Wiens A, et al. Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil. Braz J Infect Dis 2018;22:186-92.
20. Akkarathamrongsin S, Payungporn S, Thong VD, et al. Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms. World J Gastroenterol 2014;20:10599-605.
21. Karabulut N, Alacam S, Yolcu A, Onel M, Agacfidan A. Distribution of hepatitis C virus genotypes in Istanbul, Turkey. Indian J Med Microbiol 2018;36:192-6.
22. Cozzani E, Herzum A, Burlando M, Parodi A. Cutaneous manifestations of HAV, HBV, HCV. G Ital Dermatol Venereol 2019 Dec 4.
23. Patel P, Malik K, Krishnamurthy K. Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct- Acting Antivirals: A Systematic Review and Meta-Analysis. J Cutan Med Surg 2016;20:58-66.
24. Fuentes A, Mardones C, Burgos PI. Understanding the Cryoglobulinemias. Curr Rheumatol Rep 2019;21:60.
25. Nagao Y, Kimura K, Kawahigashi Y, Sata M. Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Clin Transl Gastroenterol 2016;7:179.
26. Tachi Y, Hirai T, Kojima Y, et al. Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response. Eur J Gastroenterol Hepatol 2018;3:1066-72.
27. Oeda S, Takahashi H, Yoshida H, et al. Prevalence of pruritus in patients with chronic liver disease: A multicenter study. Hepatol Res 2018;48:252-62.
28. Surjadi M. Chronic Hepatitis C Screening, Evaluation, and Treatment Update in the Age of Direct-Acting Antivirals. Workplace Health Saf 2018;66:302-9.
29. Conti F, Brillanti S, Buonfiglioli F, et al. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat 2017;24:454-63.
30. Tachi Y, Hirai T, Kojima Y, et al. Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response. Eur J Gastroenterol Hepatol 2018;30:1066-72.
31. Villani R, Monami M, Di Cosimo F, et al. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis. J Viral Hepat 2019;26:1249-56.
32. Liu CH, Su TH, Liu CJ, et al. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. J Gastroenterol Hepatol 2019;34:1620-5.
33. Ishida K, Shimakami T, Kaneko S. [The use of direct-acting antivirals in the treatment of elderly patients with hepatitis C Virus infection]. Nihon Ronen Igakkai Zasshi 2017;54:375- 80.
34. Ko SY, Choe WH. Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. Clin Mol Hepatol 2018;24:351-7.
35. Waldenström J, Lagging M. Editorial: ribavirin continues to play a role in treatment with direct-acting antivirals for hepatitis C virus-infected patients with decompensated cirrhosis. Aliment Pharmacol Ther 2017;46:1115-6.
36. Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database Syst Rev 2010;(1):005445.

APA	agirgol s, agirgol m (2021). Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. , 239 - 244. 10.4274/haseki.galenos.2021.6704
Chicago	agirgol senay,agirgol muharrem Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. (2021): 239 - 244. 10.4274/haseki.galenos.2021.6704
MLA	agirgol senay,agirgol muharrem Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. , 2021, ss.239 - 244. 10.4274/haseki.galenos.2021.6704
AMA	agirgol s,agirgol m Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. . 2021; 239 - 244. 10.4274/haseki.galenos.2021.6704
Vancouver	agirgol s,agirgol m Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. . 2021; 239 - 244. 10.4274/haseki.galenos.2021.6704
IEEE	agirgol s,agirgol m "Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study." , ss.239 - 244, 2021. 10.4274/haseki.galenos.2021.6704
ISNAD	agirgol, senay - agirgol, muharrem. "Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study". (2021), 239-244. https://doi.org/10.4274/haseki.galenos.2021.6704

APA	agirgol s, agirgol m (2021). Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. Haseki Tıp Bülteni, 59(3), 239 - 244. 10.4274/haseki.galenos.2021.6704
Chicago	agirgol senay,agirgol muharrem Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. Haseki Tıp Bülteni 59, no.3 (2021): 239 - 244. 10.4274/haseki.galenos.2021.6704
MLA	agirgol senay,agirgol muharrem Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. Haseki Tıp Bülteni, vol.59, no.3, 2021, ss.239 - 244. 10.4274/haseki.galenos.2021.6704
AMA	agirgol s,agirgol m Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. Haseki Tıp Bülteni. 2021; 59(3): 239 - 244. 10.4274/haseki.galenos.2021.6704
Vancouver	agirgol s,agirgol m Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study. Haseki Tıp Bülteni. 2021; 59(3): 239 - 244. 10.4274/haseki.galenos.2021.6704
IEEE	agirgol s,agirgol m "Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study." Haseki Tıp Bülteni, 59, ss.239 - 244, 2021. 10.4274/haseki.galenos.2021.6704
ISNAD	agirgol, senay - agirgol, muharrem. "Assessment and Management of the Dermatological Side Effects of Direct-Acting Antiviral Agent Groups Used in the Treatment of Hepatitis C: A Prospective Study". Haseki Tıp Bülteni 59/3 (2021), 239-244. https://doi.org/10.4274/haseki.galenos.2021.6704